A single-arm phase 2 study demonstrated that an anti-EGFR antibody, panitumumab, combined with neoadjuvant chemotherapy, had significant clinical activity in HER2-negative IBC, particularly in TN-IBC patients (NCT01036087; panitumumab combined with neoadjuvant chemotherapy resulted in the highest pathological complete response (pCR) rate in 8 out of 19 TN-IBC patients) [37]. Here, EGFR is linked to inflammatory breast carcinoma.